Disc Medicine (IRON) Cash from Operations (2020 - 2026)
Disc Medicine (IRON) posted quarterly Cash from Operations of 44201000.0 for Q2 2026, up 7.76% year-over-year from 41019144.34 in Q2 2025, and up 28.98% quarter-over-quarter from 62236000.0 in Q1 2026.
Disc Medicine (IRON) Cash from Operations (2020 - 2026) Analysis & Trends
Disc Medicine (IRON) has reported Cash from Operations for 7 consecutive years, with 44201000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Operations rose 7.76% year-over-year to 44201000.0; the TTM figure through Jun 2026 stood at 197536000.0 (down 47.16% YoY), while the FY2025 annual figure was 180393000.0, down 92.06% from the prior year.
- Cash from Operations advanced to 44201000.0 in Q2 2026 per IRON's latest filing, from 62236000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 7476000.0 in Q3 2023 and bottomed at 62236000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 27581666.67 across 5 years, with a median of 22684500.0 in 2023.
- Annual changes were most pronounced in 2022 — Cash from Operations jumped 42.28% — and 2025, when it sank 211.3%.
- Disc Medicine's Cash from Operations stood at 9665000.0 in 2022, then tumbled by 84.13% to 17796000.0 in 2023, then plunged by 54.94% to 27573000.0 in 2024, then slumped by 57.04% to 43300000.0 in 2025, then decreased by 2.08% to 44201000.0 in 2026.
- Business Quant data shows IRON's Cash from Operations at 44201000.0 in Q2 2026, 62236000.0 in Q1 2026, and 43300000.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Disc Medicine | 3.02 Bn | 3.02 Bn | - | -44.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44.20 Mn |
| Jun 30, 2026 | -44.20 Mn |
| Mar 31, 2026 | -62.24 Mn |
| Mar 31, 2026 | -62.24 Mn |
| Dec 31, 2025 | -43.30 Mn |
| Dec 31, 2025 | -43.30 Mn |
| Sep 30, 2025 | -47.80 Mn |
| Sep 30, 2025 | -47.80 Mn |
| Jun 30, 2025 | -47.92 Mn |
| Jun 30, 2025 | -47.92 Mn |
| Mar 31, 2025 | -41.38 Mn |
| Mar 31, 2025 | -41.38 Mn |
| Dec 31, 2024 | -27.57 Mn |
| Dec 31, 2024 | -27.57 Mn |
| Sep 30, 2024 | -17.36 Mn |
| Sep 30, 2024 | -17.36 Mn |
| Jun 30, 2024 | -15.39 Mn |
| Jun 30, 2024 | -15.39 Mn |
| Mar 31, 2024 | -33.60 Mn |
| Mar 31, 2024 | -33.60 Mn |